文献速递核素与放射性配体治疗肿瘤 PET/CT

基于90Y PET/CT剂量指标的logit模型预测肿瘤控制概率

Prediction of Tumor Control in 90Y Radioembolization by Logit Models with PET/CT-Based Dose Metrics.
PubMed 文献 · J Nucl Med · 2019-05-30

本研究纳入原发性肝癌或肝转移患者,在90Y玻璃微球放射栓塞后行90Y PET/CT体素级剂量学,评估28次治疗共89个病灶的剂量指标与肿瘤控制概率(TCP)的关系。病灶剂量-缩小分析显示mRECIST相关系数更优,联合组mRECIST总体缓解率为57%,平均吸收剂量(AD)和生物有效剂量(BED)达50% TCP分别为292 Gy和441 Gy,各剂量指标均与缓解概率显著相关(AUC 0.87-0.90,P<0.0001)。

要点

  • 90Y PET/CT剂量学中,平均AD达50% TCP为292 Gy,BED为441 Gy。
  • 各剂量指标与病灶缓解显著相关,AUC 0.87-0.90,P<0.0001。
  • 平均AD预测性能与复杂放射生物学剂量指标相当。

核心结论

  • logistic回归TCP模型显示多种剂量指标与缓解概率强相关,平均AD性能与复杂放射生物学指标相当,提示治疗计划中应考虑TCP。

研究设计与样本

  • 回顾性分析原发性肝癌或肝转移接受90Y玻璃微球放射栓塞的患者,行90Y PET/CT体素级剂量学,共28次治疗89个病灶。

主要发现

  • 病灶剂量-缩小分析中,原发与转移亚组模型参数无显著差异,mRECIST相关系数更优。
  • 联合组mRECIST总体病灶缓解率为57%。
  • 平均AD和BED达50% TCP分别为292 Gy和441 Gy。
  • 所有考虑的剂量指标(包括平均AD)均与缓解概率显著相关,AUC 0.87-0.90,P<0.0001,敏感度>0.75,特异度>0.83。
  • 非肿瘤肝AD与毒性指标无相关性。

关键数值与推荐

  • 基于mRECIST的病灶缓解定义为二分类响应,用于TCP模型拟合。
  • 50% TCP对应平均AD 292 Gy、BED 441 Gy。
  • AUC 0.87-0.90,P<0.0001,敏感度>0.75,特异度>0.83(以50% TCP阈值得出)。

临床怎么用

  • 治疗计划中可参考平均AD等剂量指标预测肿瘤控制概率,平均AD计算简便且性能与复杂指标相当。

局限性

  • 患者队列异质性大。
  • PET无法在微观尺度确定微球非均匀沉积,拟合所得放射敏感性值显著低于体外细胞培养或外照射临床研究报道值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The aim of this work was to develop models for tumor control probability (TCP) in radioembolization with 90Y PET/CT-derived radiobiologic dose metrics. Methods: Patients with primary liver cancer or liver metastases who underwent radioembolization with glass microspheres were imaged with 90Y PET/CT for voxel-level dosimetry to determine lesion absorbed dose (AD) metrics, biological effective dose (BED) metrics, equivalent uniform dose, and equivalent uniform BED for 28 treatments (89 lesions). The lesion dose-shrinkage correlation was assessed on the basis of RECIST and, when available, modified RECIST (mRECIST) at first follow-up. For a subset with mRECIST, logit regression TCP models were fit via maximum likelihood to relate lesion-level binary response to the dose metrics. As an exploratory analysis, the nontumoral liver dose-toxicity relationship was also evaluated. Results: Lesion dose-shrinkage analysis showed that there were no significant differences between model parameters for primary and metastatic subgroups and that correlation coefficients were superior with mRECIST. Therefore, subsequent TCP analysis was performed for the combined group using mRECIST only. The overall lesion-level mRECIST response rate was 57%. The AD and BED metrics yielding 50% TCP were 292 and 441 Gy, respectively. All dose metrics considered for TCP modeling, including mean AD, were significantly associated with the probability of response, with high areas under the curve (0.87-0.90, P < 0.0001) and high sensitivity (>0.75) and specificity (>0.83) calculated using a threshold corresponding to 50% TCP. Because nonuniform AD deposition by microspheres cannot be determined by PET at a microscopic scale, radiosensitivity values extracted here by fitting models to clinical response data were substantially lower than reported for in vitro cell cultures or for external-beam radiotherapy clinical studies. There was no correlation between nontumoral liver AD and toxicity measures. Conclusion: Despite the heterogeneous patient cohort, logistic regression TCP models showed a strong association between various dose metrics and the probability of response. The performance of mean AD was comparable to that of radiobiologic dose metrics that involve more complex calculations. These results demonstrate the importance of considering TCP in treatment planning for radioembolization.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Dewaraja YK, Devasia T, Kaza RK, et al. Prediction of Tumor Control in 90Y Radioembolization by Logit Models with PET/CT-Based Dose Metrics. J Nucl Med. 2019. PMID: 31147404. doi:10.2967/jnumed.119.226472

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。